Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

January 2019

Análisis agrupado de la seguridad de Tofacitinib como monoterapia o en combinación con Fármacos Antirreumáticos Modificadores de la Enfermedad Convencionales de base en una Población de Fase 3 con Artritis Reumatoide

Semin Arthritis Rheum. 2018 Dec;48(3):406-415. doi: 10.1016/j.semarthrit.2018.07.006.

Cohen S,

Kaine J,

Fan H,

In this pooled analysis of Phase 3 Tofacitinib (TOF) trials, safety profiles were generally similar between patients receiving monotherapy and combination therapy. Although selected adverse events of interest showed lower incidence rates (IRs) for TOF monotherapy patients.TOF has been studied as monotherapy and in combination with csDMARDs. In this post-hoc analysis, data were pooled from six Phase 3 TOF studies in RA patients to further examine the safety profile when used as monotherapy or in ...

Keywords:

March 2018

Experiencia Mundial de Vigilancia Después de la Comercialización de Tofacitinib en Artritis Reumatoide a lo largo de 3 Años

Rheumatol Ther 2018 Jun; 5(1):283–91

Cohen S,

Curtis JE,

DeMasi R,

Chen Y,

Fan H,

Soonasra A,

Fleischmann R

This real-world analysis of tofacitinib (TOF) revealed that AEs reported by patients with RA from 2012 to 2015 were consistent with the known safety profile of TOF – no new safety risks were identified.As of August 2017, it is estimated that more than 102 000 patients worldwide have received TOF, but TOF safety has not been evaluated in patients with real-world experience. This analysis addressed this – by evaluating the safety of TOF from post-marketing surveillance (PMS) reports from patients ...

Keywords:

Efecto de Discontinuar o Empezar Metotrexate o Glucocorticoides en la Eficacia de Tofacitinib en Pacientes con Artritis Reumatoide: Un Análisis Post Hoc

Rheumatol Ther 2018 Jun; 5(1):203–14. DOI: 10.1007/s40744-018-0093-7

Fleischmann R,

Wollenhaupt J,

Cohen S,

Wang L,

Fan H,

Bandi V,

Methotrexate (MTX) or Glucocorticoid (GC) discontinuation has little effect on CDAI response in patients given tofacitinib (TOF) for up to 3 years. Patients receiving TOF who showed initial improvements benefitted from initiation of MTX or GCs. Concomitant treatments such as MTX or GC are commonly used in combination with RA therapies to improve or accelerate clinical responses. However, their use is associated with many adverse events so clinicians aim to use them for a minimal duration.This po...

Keywords:

December 2017

Efecto de Glucocorticoides en la eficacia Clínica y Radiográfica de Tofacitinib en Pacientes con Artritis Reumatoide: Un análisis Posthoc de datos desde 6 estudios fase III

J Rheumatol 2018 Feb; 45(2):177-87

Nash P,

Fan H,

Kwok K,

Bananis E,

Fleischmann R

In this post hoc analysis, six Phase 3 studies were used to analyse the effect of glucocorticoids (GC) on the efficacy of tofacitinib (TOF) in patients with RA. Concomitant use of GC did not affect the clinical or radiographic outcomes of patients treated with TOF. Data from all six clinical trials were evaluated, with four studies (ORAL Scan, ORAL Standard, ORAL Sync and ORAL Step) being pooled for analysis. In these studies, MTX was used as a comparison and patients were required to maintain a...

Keywords:

November 2017

Herpes Zoster y Tofacitinib: Resultados Clínicos y Riesgo de Terapia Concomitante

Arthritis Rheumatol 2017;69(10):1960–68

Wang L,

Fan H,

Chen C,

Bananis E

The results of this analysis of patients with herpes zoster (HZ) within the global tofacitinib (TOF) RA programme suggest that there is likely to be a greater HZ risk in patients receiving TOF and glucocorticoids compared with patients receiving TOF monotherapy.The global TOF RA development programme comprised 2 Phase 1, 9 Phase 2, 6 Phase 3 and 2 long-term extension studies. These studies included 6192 patients; data were reviewed to identify cases of HZ. Crude incidence rates of number of pati...

Keywords:

August 2017

Análisis del cáncer de piel no melanoma a través del programa clínico de Tofacitinib en la Artritis Reumatoide

Clin Exp Rheumatol 2017;35:614–22

Lee EB,

Chen Y,

Geier J,

Andrews J,

Kaur M,

Fan H,

Nduaka CI

Because non-melanoma skin cancer (NMSC) is one of the most common malignancies associated with RA immunomodulatory therapies, this analysis looked to determine the rate of NMSC incidence per 100 patient-years in patients with RA receiving TOF in the clinical trial programme. The Phase 1, 2, and 3 IRs (combined) for both TOF 5- and 10 mg were low and comparable to those of adalimumab, MTX and placebo, IRs remained stable over time. TOF doses used in the 2 Phase 1; 8 Phase 2; and 6 Phase 3 studies...

Keywords:

April 2015

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

Ann Rheum Dis. 2015 Mar 20. pii: annrheumdis-2014-207191. doi: 10.1136/annrheumdis-2014-207191. [Epub ahead of print]

Winthrop KL,

Silverfield J,

Racewicz A,

Neal J,

Lee EB,

Hrycaj P,

Gomez-Reino J,

Soma K,

Mebus C,

Wilkinson B,

Hodge J,

Fan H,

Wang T,

Bingham CO 3rd.

The increased risk of serious infection among RA patients means vaccinations against pneumococcus and influenza are recommended in this group of patients. Studies evaluating immune response to these vaccines in conjunction with DMARD therapy can provide clinicians with important information relating to things such as timing of vaccination.

This study aimed to assess the effect of tofacitinib on vaccine responses to PPSV-23 and the trivalent seasonal influenza vaccine in those whom tofacit...